NeuroVive reports positive pre-clinical results in NASH

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Nov 1, 2016 at 4:00 AM

Lund, Sweden, November 1, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced positive pre-clinical results with one of its cyclophilin inhibitors, NVP018, in an experimental model of the chronic and common liver condition NASH (non-alcoholic steatohepatitis). The NASH project is in line with the company’s updated business strategy which includes increased and accelerated efforts in moving high potential discovery projects forward with the aim of out-licensing them in the preclinical phase. The present data shows that NVP018 prevents fibrosis development in a well -validated experimental model of NASH. Further experimental activities with NVP018 within NASH are ongoing. In addition, NeuroVive is developing a new class of compounds with a different mode of action that may offer complementary treatment of NASH. This discovery project is based on NeuroVive’s core competence in mitochondrial energy regulation and the partner company Isomerase’s innovative chemistry capabilities. “The current experimental result in NASH is an excellent example of the strength of the research within NeuroVive and the successful collaboration with Isomerase. The result at hand is an important step forward in our continued development for out-licensing in this therapeutic area”, said Erik Kinnman, CEO NeuroVive. “Given the huge patient population and the high unmet medical need, we see our results and activities in NASH as high potential near term value drivers and potential revenue sources in NeuroVive’s pipeline.” The company has implemented a business model going forward that contains two parts. One part involves high potential large indication projects like NASH, for out-licensing in the preclinical phase. The second part is to take drugs for rare diseases with high unmet medical need through clinical development and into the market. NeuroVive’s core research and development area continues to be mitochondrial medicine, with the aim to offer new treatment options to patients with unmet medical needs. There is a continuous growing understanding for the importance of mitochondrial function in many diseases. About NASH NASH – non-alcoholic steatohepatitis – is a progressive disease that can lead to liver cirrhosis and the development of hepatocellular carcinoma. NASH liver damage is caused by a buildup of fat and inflammatory changes in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease (NAFLD) that is one of the most common conditions worldwide. It is estimated that 20 % of the global population suffers from NAFLD and about one-third of the population in the US. There is a strong association between NASH and a variety of metabolic syndromes like diabetes and obesity. Approximately 3-5 % of Americans (approx. 15 million people) suffer from NASH and there are currently no registered drugs for the treatment of this condition.1) 1) Vernon G. et al. Aliment Pharmacol Ther. 2011;34(3):274-85 About NVP018 NVP018 is a potent non-immunosuppressive cyclophilin inhibitor within NeuroVive’s new compound class Sangamides. In this cyclophilin inhibitor chemical family, NVP018 is the oral version of its lead compound (NV556) which has undergone extensive preclinical development. About NeuroVive NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company’s strategy is to take drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production. NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to neurological and metabolic diseases such as NASH. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com Charles Athle Nelson, NeuroVive US representative, Tel +1 212 961 6277 or ir.usa@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48 www.neurovive.com This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CET on November 1, 2016.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SAHZU Hospital Earns GHA Distinction for Travel Care

A New Benchmark in International Patient Experience When a hospital sets the standard for treating foreign patients like family, it deserves recognition. That's exactly what's happened at The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU), which just snagged an impressive accolade from Global Healthcare Accreditation (GHA). For anyone keeping...

New Dog Leash Innovation Eases Dog Owner Struggles

A real game-changer in dog-walking gear could be sitting right under our noses, and it's coming straight from an inventor in Grand Junction, Colorado. Picture this: you're navigating a tight store aisle, juggling a toddler, a shopping cart, and a squirming dog. This ain't exactly the time for your leash to make life harder. Enter the SHOP & WALK DOG LEASH. This doohickey...

Maritime Safety Urged After New Orleans Vessel Incident

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

TuHURA Unveils Q3 2026 Gains Amid Strategic Moves

TuHURA's Strategic Maneuver: A Deeper Dive TuHURA Biosciences, folks, has just laid out their third-quarter map, and it ain't just scribbles. Amidst the Tampa heat, they're not only crunching numbers but peddling some pretty hefty science, too. Let's dig into what these folks have cooked up this time. Game-Changing Results and Collaborations Now, let's not beat around the...

vVARDIS Readies for Big Day on NYSE—IPO Set to Shine

vVARDIS Stepping into the Spotlight of the NYSE Alright, folks, here's one that could make some waves. vVARDIS is gearing up for its NYSE debut, trading under the ticker VVVV. They're no small fry talking about 9.72 million shares priced at 18 bucks a pop. This isn't just any run-of-the-mill company; they claim to have the first peptide-containing formulation for early...

Common ADHD Accommodations Fail to Boost Performance

Rethink ADHD Accommodations When it comes to ADHD, everyone ties the classic school accommodations to success. You give kids extra time, a quieter spot, and regular breaks, and you figure that's the magic formula, right? Well, hold onto your hats, because a fresh study out of Florida International University is flipping that script. Turns out, all those accommodations we...

JardogsHealth Taps Industry Titans for Growth Council

JardogsHealth: A New Chapter with Strategic Insights You've got to admire when a company rounds up a top-tier brain trust. Such is the case with JardogsHealth, the healthcare AI outfit nestled in Hillsboro, Illinois, as they align their future alongside heavyweights who’ve maneuvered through multiple industries and come out thriving. Their brand-new council includes...

Enjay Acquires New Method: A Strategic Synergy Unfolds

Enjay's Bold Move into New Territory Here's a headline that doesn’t just flutter past like yesterday's news. Enjay Converters Ltd, straight from Cobourg, Ontario, has clinched a deal that looks like it might just shake things up a bit on the food packaging scene. They’ve bagged New Method Packaging LLC, another big player, but this time from the heartland of...

DraftKings Shares Tumble, Investors Grapple with Losses

DraftKings' Bold Moves Hit Investor Pockets Hard It ain't every day you see a company gamble nearly $700 million and come out with egg on its face. Yet, that's what DraftKings (NASDAQ: DKNG) seems to have done, and now it's shareholders who might be left holding the bag. On November 6, 2026, when DraftKings admitted it was doubling down on its Predictions business...

Southwest Airlines Elevates Inflight Gaming Experience

Southwest Takes Gaming to New Heights If you thought inflight entertainment had hit its peak, think again. Southwest Airlines, under the ticker NYSE:LUV, just boarded the high-stakes gaming train, broadcasting real-time gaming tournaments thanks to Starlink’s satellite-powered WiFi. It's the kind of bold move that makes you sit up and wonder if we're hovering right at...